close
close

Schall Law Firm encourages you

LOS ANGELES, June 11, 2024 (GLOBE NEWSWIRE) — Schall Law Firmnational shareholder rights litigation firm, reminds investors of class action lawsuit against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) for violating Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities Exchange Commission and Stock Exchanges.

Investors who purchased the Company’s securities between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before June 25, 2024.

If you are a shareholder who has suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335 to discuss your rights free of charge. You can also contact us via the company’s website at: www.schallfirm.comor by email to [email protected].

In this case, the class has not yet been certified and you are not represented by an attorney until you are certified. If you choose to take no action, you may remain an absent member of the class.

The complaint alleges that the Company made false and misleading statements to the market. 20% of patients enrolled in the Akero SYMMETRY trial had cryptogenic cirrhosis and did not have definitive NASH at baseline. These patients did not have biopsy-proven compensated cirrhosis. These patients were excluded from the SYMMETRY trial when calculating secondary NASH resolution endpoints. The Company influenced the results of the study and increased the likelihood of failure to meet the primary endpoint by introducing confounding factors into the study. The SYMMETRY study did not comply with FDA guidelines because it did not rule out potential causes of cirrhosis in each patient. Based on these facts, the Company’s public statements were false and materially misleading throughout the audit period. When the market learned the truth about Akero, investors suffered losses.

Join the cause and recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class actions and shareholder rights disputes.

This press release may be considered attorney advertising in some jurisdictions under applicable law and ethical rules.

CONTACT:

Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

Schall Law Firm